## REMARKS

The above-identified application has been carefully reviewed and amended in light of the office action mailed on November 18, 2011. All fees relating to this communication can be charged to Deposit Account No. 01-0885.

The applicant affirms the election of Species A, Figures 1-3, made by applicant in telephone conversation between the Examiner and the undersigned on November 11, 2011. Claims 52-62 have been withdrawn as being directed to the non-elected species.

Without conceding the correctness of any of the Examiner's rejections, applicant has amended the specification, Drawings and claim 51 in order to facilitate prosecution of the above-identified application and more clearly define certain embodiments of the invention for which patent protection is sought. By the amendments, Applicants do not acquiesce to the propriety of any of the Examiner's rejections and do not disclaim any subject matter to which Applicants are entitled. Cf. Warner Jenkinson Co. v. Hilton-Davis Chem. Co., 41 U.S.P.Q.2d 1865 (U.S. 1997).

The specification has been amended by inserting a paragraph before the first sentence on page 1, stating the priority claims of the application under 35 U.S.C 371.

Applicant appreciates the Examiner's thorough review of the application and identification of inconsistencies in some of the reference numerals between the Drawings and specification as filed.

Accordingly, the specification has been amended to conform the specification with the Drawings for purposes of clarification and without adding new matter.

In addition, one sheet of Replacement Drawings is provided which adds reference numeral 524 to Figure 22, which identifies the lumen as described in the specification. No new matter is added by this amendment.

Applicant submits that the present amendments to the specification and Drawings overcome each of the objections under 37 CFR 1.84(p)(5) and thus requests they be withdrawn.

Claim 51 has been amended without prejudice. Applicant expressly reserves the right to seek patent protection for the original claims and all other claims supported by the above-identified application, for example, in one or more later-filed related applications.

Specifically, claim 51 as amended now further recites that the rotatable drum includes a "sponge-like material for distributing the medicament". Applicant submits that this feature of the claimed invention is shown in Figure 3 as element 40, and described at the bottom of page 13 of the specification as filed.

Claim 51 has been rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over U.S. Publication No. 2004/0087992 (Garstein et al.), and in view of U.S. Patent No. 6,475,160 (Sher) Applicant traverses this rejection as it pertains to the claims as amended.

Applicant submits that neither Garstein nor Sher, alone or in combination, disclose, teach or suggest the invention now claimed.

For example, Neither Garstein nor Sher disclose, teach or even suggest a multi-site injection system comprising a rotatable drum having an outer surface with microprotrusions thereon, and said rotatable drum including a sponge-like material for distributing medicament, as now recited in claim 51.

For at least these reasons, applicant submits that the present claims are not obvious in view of, and are patentable over, Garstein et al. in view of Sher, under 35 U.S.C. 103(a).

Applicants respectfully submits that the application is now in condition for allowance, and requests a favorable reply. The Examiner is invited to call the undersigned attorney if any issues remain unresolved.

Please use Deposit Account 01-0885 for the payment of any extension of time fees, and/or the payment of any other fees due in connection with the present response.

Dated: April 18, 2012 Respectfully submitted,

/Linda Allyson Fox/ Linda Allyson Fox Reg. No. 38,883 Attorney for Applicant

Please direct all inquiries and correspondence to:

Linda A. Fox, Esq.
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: 714.246-4758/Fax: 714.246-4249